- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02572778
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (UCL-Xenog)
March 18, 2021 updated by: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:
generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer
- perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
- evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
- evaluate biomarkers of drug sensitivity
- study primary and secondary (acquired) resistance in these models
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aline Gillain, MedSciences
- Phone Number: 5498 00322764
- Email: aline.gillain@uclouvain.be
Study Contact Backup
- Name: Sandra Schmitz, MD, PhD
- Phone Number: 5470 00322764
- Email: sandra.schmitz@uclouvain.be
Study Locations
-
-
-
Brussels, Belgium, 1200
- Recruiting
- Cliniques Universitaires Saint-Luc
-
Contact:
- Jean-Pascal Machiels, MD, PhD
- Email: jean-pascal.machiels@uclouvain.be
-
Contact:
- Aline Gillain, MedSciences
- Email: aline.gillain@uclouvain.be
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All patients with a primary advanced or recurrent head and neck tumor.
- Inclusion preoperatively or before biopsy
- Written informed consent prior to surgery or biopsy
Description
Inclusion Criteria:
- In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
- Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
- Follow-up data should be available
- Patients with recurrent disease are allowed
- Written informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides
Time Frame: 10 years
|
Identification of the biomarkers of new cancer therapies for head and neck
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques
Time Frame: 10 years
|
Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques
|
10 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2025
Study Registration Dates
First Submitted
September 22, 2015
First Submitted That Met QC Criteria
October 8, 2015
First Posted (Estimate)
October 9, 2015
Study Record Updates
Last Update Posted (Actual)
March 19, 2021
Last Update Submitted That Met QC Criteria
March 18, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCL-ONCO2015-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of the Head and Neck
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Hi-Q Marine Biotech International, Ltd.RecruitingSquamous Cell Carcinomas of the Head and NeckTaiwan
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
University of Southern CaliforniaSanofiTerminatedCarcinoma of the Head and NeckUnited States
-
Queensland HealthMerck Sharp & Dohme LLCRecruitingHead and Neck Cancer | Cutaneous Squamous Cell Carcinoma of the Head and NeckAustralia
Clinical Trials on Local biopsy in the tumor
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceTerminated
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
Shandong UniversityCompletedHyperplasia | Colorectal Neoplasia | Mucosal Microbiome | Colorectal InflammationChina
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Duke UniversitySuspendedKidney Cancer | Prostate Cancer | Bladder Cancer | Genito Urinary CancerUnited States
-
Ulrik LassenRecruitingUnspecified Adult Solid Tumor, Protocol SpecificDenmark
-
M.D. Anderson Cancer CenterUnited States Department of DefenseCompletedLung CancerUnited States
-
The Netherlands Cancer InstituteKU LeuvenRecruitingSoft Tissue Sarcoma | Xenograft Model | 2D/3D Cell CulturesNetherlands
-
GlaxoSmithKlineTerminatedNeoplasms | Lung Cancer, Non-Small CellUnited States, Spain
-
Maastricht Radiation OncologyActive, not recruiting